SEARCH

SEARCH BY CITATION

References

  • 1
    Kang YJ, Olson MO, Jones C, Busch H ( 1975) Nucleolar phosphoproteins of normal rat liver and Novikoff hepatoma ascites cells. Cancer Res. 35: 14701475.
  • 2
    Schmidt-Zachmann MS, Hugle-Dorr B, Franke WW ( 1987) A constitutive nucleolar protein identified as a member of the nucleoplasmin family. EMBO J. 6: 18811890.
  • 3
    Borer RA, Lehner CF, Eppenberger HM, Nigg EA ( 1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 56: 379390.
  • 4
    Murano K, Okuwaki M, Hisaoka M, Nagata K ( 2008) Transcription regulation of the rRNA gene by a multifunctional nucleolar protein, B23/nucleophosmin, through its histone chaperone activity. Mol Cell Biol. 28: 31143126.
  • 5
    Savkur RS, Olson MO ( 1998) Preferential cleavage in pre-ribosomal RNA by protein B23 endoribonuclease. Nucleic Acids Res. 26: 45084515.
  • 6
    Maggi LB, Jr, Kuchenruether M, Dadey DY, Schwope RM, Grisendi S, Townsend RR, Pandolfi PP, Weber JD ( 2008) Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol. 28: 70507065.
  • 7
    Okuwaki M, Iwamatsu A, Tsujimoto M, Nagata K ( 2001) Identification of nucleophosmin/B23, an acidic nucleolar protein, as a stimulatory factor for in vitro replication of adenovirus DNA complexed with viral basic core proteins. J Mol Biol. 311: 4155.
  • 8
    Okuwaki M, Matsumoto K, Tsujimoto M, Nagata K ( 2001) Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 506: 272276.
  • 9
    Wang W, Budhu A, Forgues M, Wang XW ( 2005) Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 7: 823830.
  • 10
    Colombo E, Alcalay M, Pelicci PG ( 2011) Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene. 30: 25952609.
  • 11
    Frehlick LJ, Eirin-Lopez JM, Ausio J ( 2006) New insights into the nucleophosmin/nucleoplasmin family of nuclear chaperones. Bioessays. 29: 4959.
  • 12
    Namboodiri VMH, Akey IV, Schmidt-Zachmann MS, Head JF, Akey CW ( 2004) The structure and function of Xenopus NO38-core, a histone chaperone in the nucleolus. Structure. 12: 21492160.
  • 13
    Lee HH, Kim HS, Kang JY, Lee BI, Ha JY, Yoon HJ, Lim SO, Jung G, Suh SW ( 2007) Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface. Proteins. 69: 672678.
  • 14
    Szebeni A, Olson MO ( 1999) Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 8: 905912.
  • 15
    Grisendi S, Mecucci C, Falini B, Pandolfi PP ( 2006) Nucleophosmin and cancer. Nat Rev Cancer. 6: 493505.
  • 16
    Lindstrom MS ( 2011) NPM1/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int. 2011: 195209.
  • 17
    Emmott E, Hiscox JA ( 2009) Nucleolar targeting: the hub of the matter. EMBO Rep. 10: 231238.
  • 18
    Hingorani K, Szebeni A, Olson MO ( 2000) Mapping the functional domains of nucleolar protein B23. J Biol Chem. 275: 2445124457.
  • 19
    Yu Y, Maggi LB, Jr, Brady SN, Apicelli AJ, Dai MS, Lu H, Weber JD ( 2006) Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 26: 37983809.
  • 20
    Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H ( 2002) Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem. 66: 22392242.
  • 21
    Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli MF ( 2007) Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 92: 519532.
  • 22
    Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF; GIMEMA Acute Leukemia Working Party ( 2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 352: 254266.
  • 23
    Falini B, Nicoletti I, Martelli MF, Mecucci C ( 2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 109: 874885.
  • 24
    Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T ( 2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 117: 11091120.
  • 25
    Grummitt CG, Townsley FM, Johnson CM, Warren J, Bycroft M ( 2008) Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol Chem. 283: 2332623332.
  • 26
    Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, Brown P, Pane F, Mancini M, Martelli MP, Pileri S, Haferlach T, Haferlach C, Schnittger S ( 2008) NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica. 93: 439442.
  • 27
    Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R, Martelli MP, Liso A, Mecucci C, Fabbiano F, Martelli MF, Henderson BR, Falini B ( 2007) Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. 67: 62306237.
  • 28
    Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF, Nicoletti I, Rodeghiero F, Falini B ( 2007) Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. 21: 10991103.
  • 29
    Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, Nicoletti I ( 2006) Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 107: 45144523.
  • 30
    Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, Diverio D, Nicoletti I, Pacini R, Tabarrini A, Galletti BV, Mannucci R, Roti G, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo-Coco F, Saglio G, Pelicci PG, Martelli MF, Mecucci C ( 2006) Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 108: 19992005.
  • 31
    Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD, Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Eds. ( 2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC), pp 110123.
  • 32
    Scaloni F, Gianni S, Federici L, Falini B, Brunori M ( 2009) Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance. FASEB J. 23: 23602365.
  • 33
    Scaloni F, Federici L, Brunori M, Gianni S ( 2010) Deciphering the folding transition state structure and denatured state properties of nucleophosmin C-terminal domain. Proc Natl Acad Sci USA. 107: 54475452.
  • 34
    Chiarella S, De Cola A, Scaglione GL, Carletti E, Graziano V, Barcaroli D, Lo Sterzo C, Di Matteo A, DI Ilio C, Falini B, Arcovito A, De Laurenzi V, Federici L (in press) Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA. Nucleic Acids Res.; doi:10.1093/nar/gkt001.
  • 35
    Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti I ( 2009) Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 23: 17311743.
  • 36
    Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA, Nicoletti I, Mannucci R, Pucciarini A, Bigerna B, Martelli MF, Mecucci C, Drexler HG, Falini B ( 2005) Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 19: 17601767.
  • 37
    Dumbar TS, Gentry GA, Olson MO ( 1989) Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry. 28: 94959501.
  • 38
    Wang D, Baumann A, Szebeni A, Olson MO ( 1994) The nucleic acid binding activity of nucleolar protein B23.1 resides in its carboxyl-terminal end. J Biol Chem. 269: 3099430998.
  • 39
    Herrera JE, Savkur R, Olson MO ( 1995) The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res. 23: 39743979.
  • 40
    Palaniswamy V, Moraes KC, Wilusz CJ, Wilusz J ( 2006) Nucleophosmin is selectively deposited on mRNA during polyadenylation. Nat Struct Mol Biol. 13: 429435.
  • 41
    Mukudai Y, Kubota S, Kawaki H, Kondo S, Eguchi T, Sumiyoshi K, Ohgawara T, Shimo T, Takigawa M ( 2008) Posttranscriptional regulation of chicken ccn2 gene expression by nucleophosmin/B23 during chondrocyte differentiation. Mol Cell Biol. 28: 61346147.
  • 42
    Gurumurthy M, Tan CH, Ng R, Zeiger L, Lau J, Lee J, Dey A, Philp R, Li Q, Lim TM, Price DH, Lane DP, Chao SH ( 2008). Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol. 378: 302317.
  • 43
    Dhar SK, Lynn BC, Daosukho C, St Clair DK ( 2004) Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem. 279: 2820928219.
  • 44
    Xu Y, Fang F, Dhar SK, St Clair WH, Kasarskis EJ, St Clair DK ( 2007) The role of a single-stranded nucleotide loop in transcriptional regulation of the human sod2 gene. J Biol Chem. 282: 1598115994.
  • 45
    Federici L, Arcovito A, Scaglione GL, Scaloni F, Lo Sterzo C, Di Matteo A, Falini B, Giardina B, Brunori M ( 2010) Nucleophosmin C-terminal leukemia-associated domain interacts with G-rich quadruplex forming DNA. J Biol Chem. 285: 3713837149.
  • 46
    Huppert JL ( 2008) Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem Soc Rev. 37: 13751384.
  • 47
    Neidle S ( 2009) The structures of quadruplex nucleic acids and their drug complexes. Curr Opin Struct Biol. 19: 239250.
  • 48
    Huppert JL, Balasubramanian S ( 2005) Prevalence of quadruplexes at the human genome. Nucleic Acid Res. 33: 29082916.
  • 49
    Bugaut A, Balasubramanian S ( 2012) 5′-UTR RNA G-quadruplexes: translation regulation and targeting. Nucleic Acids Res. 40: 47274741.
  • 50
    Sissi C, Gatto B, Palumbo M ( 2011) The evolving world of protein-G-quadruplex recognition: a medicinal chemist's perspective. Biochimie. 93: 12191230.
  • 51
    Gonzalez V, Hurley LH ( 2010) The cMYC NHEIII (1): function and regulation. Annu Rev Pharmacol Toxicol. 50: 111129.
  • 52
    Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA ( 2011) Demonstration that drug-targeted downregulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem. 286: 4101841027.
  • 53
    Gallo A, Lo Sterzo C, Mori M, Di Matteo A, Bertini I, Banci L, Brunori M, Federici L ( 2012) Structure of nucleophosmin DNA-binding domain and analysis of its complex with a G-quadruplex sequence from the c-MYC promoter. J Biol Chem. 287: 2653926548.
  • 54
    Tompa P, Fuxreiter M ( 2008) Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci. 33: 28.
  • 55
    Guo X, Bulyk ML, Hartemink AJ ( 2012) Intrinsic disorder within and flanking the DNA-binding domains of human transcription factors. Pac Symp Biocomput. 2012: 104115.
  • 56
    Marasco D, Ruggiero A, Vascotto C, Poletto M, Scognamiglio PL, Tell G, Vitagliano L ( 2013) Role of mutual interactions in the chemical and thermal stability of nucleophosmin NPM1 domains. Biochem Biophys Res Commun. 430: 523528.
  • 57
    Grummt I ( 1999) Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog Nucleic Acid Res Mol Biol. 62: 109154.
  • 58
    Drygin D, Siddiqui-Jain A, O'Brien S, Schwaebe M, Lin A, Bliesath J, Ho CB, Proffitt C, Trent K, Whitten JP, Lim JK, Von Hoff D, Anderes K, Rice WG ( 2009) Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 69: 76537661.
  • 59
    Ramos-Echazábal G, Chinea G, García-Fernández R, Pons T ( 2012) In silico studies of potential phosphoresidues in the human nucleophosmin/B23: its kinases and related biological processes. J Cell Biochem. 113: 23642374.
  • 60
    Beckmann R, Buchner K, Jungblut PR, Eckerskorn C, Weise C, Hilbert R, Hucho F ( 1992) Nuclear substrates of protein kinase C. Eur J Biochem. 210: 4551.
  • 61
    Okuwaki M, Tsujimoto M, Nagata K ( 2002) The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype. Mol Biol Cell. 13: 20162030.
  • 62
    Amin MA, Matsunaga S, Uchiyama S, Fukui K ( 2008) Nucleophosmin is required for chromosome congression, proper mitotic spindle formation, and kinetochore-microtubule attachment in HeLa cells. FEBS Lett. 582: 38393844.
  • 63
    Yao J, Fu C, Ding X, Guo Z, Zenreski A, Chen Y, Ahmed K, Liao J, Dou Z, Yao X ( 2004) Nek2A kinase regulates the localization of numatrin to centrosome in mitosis. FEBS Lett. 575: 112118.
  • 64
    Negi SS, Olson MO ( 2006) Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23. J Cell Sci. 119: 36763685.
  • 65
    Shandilya J, Swaminathan V, Gadad SS, Choudhari R, Kodaganur GS, Kundu TK ( 2009). Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. Mol Cell Biol. 29: 51155127.
  • 66
    Liu X, Liu Z, Jang SW, Ma Z, Shinmura K, Kang S, Dong S, Chen J, Fukasawa K, Ye K ( 2007) Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci USA. 104: 96799684.
  • 67
    Haindl M, Harasim T, Eick D, Muller S ( 2008). The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep. 9: 273279.
  • 68
    Wulff JE, Siegrist R, Myers AG ( 2007) The natural product avrainvillamide binds to the oncoprotein nucleophosmin. J Am Chem Soc. 129: 144414451.
  • 69
    Gjerset RA ( 2006) DNA damage, p14arf, nucleophosmin (NPM/B23) and cancer. J Mol Histol. 37: 239251.
  • 70
    Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B, Pucciarini A, Pileri S, Meloni G, Martelli MF, Haferlach T, Schnittger S ( 2008) Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica. 93: 775779.
  • 71
    Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, Meani N, Diverio D, Bernard L, Tizzoni L, Volorio S, Luzi L, Colombo E, Lo Coco F, Mecucci C, Falini B, Pelicci PG ( 2005) Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 106: 899902.
  • 72
    Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B ( 2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA. 105: 39453950.
  • 73
    Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, Pacini R, Tabarrini A, Ciurnelli R, Gionfriddo I, Manes N, Rossi R, Giunchi L, Oelschlägel U, Brunetti L, Gemei M, Delia M, Specchia G, Liso A, Di Ianni M, Di Raimondo F, Falzetti F, Del Vecchio L, Martelli MF, Falini B ( 2010) CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 116: 39073922.
  • 74
    Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D ( 2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 115: 19761984.
  • 75
    Falini B, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli MP ( 2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? Blood Rev. 25: 247254.
  • 76
    Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B ( 2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 106: 37333739.
  • 77
    Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group ( 2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 358: 19091918.
  • 78
    Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci PG ( 2006) Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 66: 30443050.
  • 79
    Bonetto P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E ( 2008) Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 182: 1926.
  • 80
    Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Ang ST, Tay KG, Koh LP, Yeoh AE, Koay ES, Mok YK, Lim TM ( 2010) Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood. 116: 32863296.
  • 81
    Noguera NI, Song MS, Divona M, Catalano G, Calvo KL, García F, Ottone T, Florenzano F, Faraoni I, Battistini L, Colombo E, Amadori S, Pandolfi PP, Lo-Coco F (in press) Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia.; doi:10.1038/leu.2012.314.
  • 82
    Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR ( 2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA. 105: 1036010365.
  • 83
    Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thöny B, Sancho J, Martinez A ( 2008) Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest. 118: 28582867.
  • 84
    Joerger AC, Fersht AR ( 2010) The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol. 2: a000919.